US EditionIndustry experts weigh in on US tariff exemption for Indian pharma amid section 232 review - Express Pharma
Summary by Express Pharma
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
Industry experts weigh in on US tariff exemption for Indian pharma amid section 232 review - Express Pharma
Sudarshan Jain, Secretary General, Indian Pharmaceutical Alliance (IPA): “The recent Executive Order by the US Administration excludes the pharmaceutical sector from immediate tariff imposition. The sector is being reviewed under Section 232 investigation. Generic medicines are important for affordable healthcare in the US and typically operate on razor-thin margins. Ensuring their consistent availability is critical for patient care. India–US p…
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
